KRTX - Karuna Therapeutics Inc Stock Price, Fair Value and News

$329.83

Market Closed as of 18 Mar 2024, 04:00 pm ET

KRTX Stock Valuation Analysis

Valuation

Max Portfolio %

KRTX Price Action

KRTX RSI Chart

KRTX Stock Valuation Analysis

Valuation

Max Portfolio %

KRTX Valuation

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

KRTX Fundamentals

KRTX Revenue

KRTX Earnings

KRTX Profitability

KRTX Investor Care

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

Net sales

Year	Q1	Q2	Q3	Q4
2023	11.3M	6.0M	5.9M	654.0K
2022	-	28.2M	19.4M	10.6M
2021	2.1M	1.4M	19.2M	37.0M
2020	3.8M	4.1M	4.0M	3.3M
2019	648.0K	1.3M	1.9M	2.5M
2018	-	-	-	25.0K

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About Karuna Therapeutics Inc

Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate includes KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of various peripheral tissues and dementia-related psychosis, including Alzheimer's disease. The company also focuses on developing other muscarinic-targeted drug candidates; and intends to develop lead candidature TRPC4/5 and KAR-2618 for the treatment of mood and anxiety disorders. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company, and Zai Lab (Shanghai) Co., Ltd; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

CEO	Mr. William Meury
WEBSITE	karunatx.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	210